1. Improved Immune Responses Against Zika Virus After Sequential Dengue and Zika Virus Infection in Humans
- Author
-
Felix G. Delgado, Anavaj Sakuntabhai, Jaime E. Castellanos, Etienne Simon-Loriere, Claude Roth, Consuelo Romero-Sánchez, Karina I. Torres, Castellanos, Jaime [0000-0003-1596-8383], Romero-Sánchez, Consuelo [0000-0002-6973-7639], Delgado Tiria, Felix Giovanni [0000-0001-6685-7507], Universidad El Bosque [Bogota], Génétique fonctionnelle des maladies infectieuses - Functional Genetics of Infectious Diseases, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), The research leading to these results has received funding from the 'Integrative Biology of Emerging Infectious Disease' Labex (Laboratoire d’excellence) under Grant Agreement number ANR-10-LABX-62-IBEID (French Government’s 'Investissements d’Avenir' program), from the European Commission Seventh Framework Program [FP7/20072–013] for the DENFREE project under Grant Agreement no. 282378, and from the Prix Duquesne. F.G.D. is registered in the Ecole Doctorale BioSPC (Université Paris Diderot) and has a PhD grant from the Colombian Department of Sciences, Technology, and Innovation (COLCIENCIAS) through the doctoral scholarship program number 679., ANR-10-LABX-0062,IBEID,Integrative Biology of Emerging Infectious Diseases(2010), European Project: 282378,EC:FP7:HEALTH,FP7-HEALTH-2011-single-stage,DENFREE(2012), and Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur [Paris]
- Subjects
cross-reactive T cells ,0301 basic medicine ,antibody-dependent-enhancement (ADE) ,T-Lymphocytes ,viruses ,lcsh:QR1-502 ,MESH: Colombia ,MESH: Dengue ,Adaptive Immunity ,Dengue virus ,Antibodies, Viral ,medicine.disease_cause ,lcsh:Microbiology ,MESH: Antibodies, Neutralizing ,Zika virus ,Dengue fever ,Dengue ,T-Cell Epitopes ,0302 clinical medicine ,Epítopos ,0303 health sciences ,B-Lymphocytes ,biology ,Zika Virus Infection ,ELISPOT ,virus diseases ,Cross-reactive T cells ,Antígenos ,virology ,3. Good health ,MESH: Leukocytes, Mononuclear ,Infectious Diseases ,[SDV.IMM.IA]Life Sciences [q-bio]/Immunology/Adaptive immunology ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,Antibody ,Virus zika ,MESH: Interferon-gamma ,030231 tropical medicine ,T-cell epitopes ,MESH: Zika Virus ,Immunodominance ,Colombia ,Article ,Interferon-gamma ,03 medical and health sciences ,MESH: Zika Virus Infection ,Immune system ,Immunity ,MESH: B-Lymphocytes ,Virology ,Virus del dengue ,medicine ,Humans ,zika virus ,neutralizing antibodies ,030304 developmental biology ,MESH: Humans ,immunodominance ,dengue virus ,biochemical phenomena, metabolism, and nutrition ,medicine.disease ,biology.organism_classification ,Antibodies, Neutralizing ,MESH: T-Lymphocytes ,030104 developmental biology ,Leukocytes, Mononuclear ,biology.protein ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,MESH: Adaptive Immunity ,MESH: Antibodies, Viral ,030215 immunology - Abstract
The high levels of dengue-virus (DENV) seroprevalence in areas where the Zika virus (ZIKV) is circulating and the cross-reactivity between these two viruses have raised concerns on the risk of increased ZIKV disease severity for patients with a history of previous DENV infections. To determine the role of DENV preimmunity in ZIKV infection, we analyzed the T- and B-cell responses against ZIKV in donors with or without previous DENV infection. Using peripheral blood mononuclear cells (PBMCs) from donors living in an endemic area in Colombia, we have identified, by interferon (IFN)-&gamma, enzyme-linked immunospot (ELISPOT) assay, most of the immunodominant ZIKV T-cell epitopes in the nonstructural (NS) proteins NS1, NS3, and NS5. Analyses of the T- and B-cell responses in the same donors revealed a stronger T-cell response against peptides conserved between DENV and ZIKV, with a higher level of ZIKV-neutralizing antibodies in DENV-immune donors in comparison with DENV-naï, ve donors. Strikingly, the potential for antibody-mediated enhancement of ZIKV infection was reduced in donors with sequential DENV and ZIKV infection in comparison with donors with DENV infection only. Altogether, these data suggest that individuals with DENV immunity present improved immune responses against ZIKV.
- Published
- 2018
- Full Text
- View/download PDF